Sanofi Analysis: $133B Raised
What is Sanofi?
AI-powered biopharma company focused on innovative healthcare solutions.
Employees
10001+
Founded
1973
Valuation
$132.66 billion
HQ Full Address
54 Rue La Boétie, Paris, Île-de-France 75008, France
Revenue Growth Rate
5.11%
Product Features & Capabilities
- Innovative medicines across various therapeutic areas
- Vaccines for infectious diseases
- Advanced R&D in immunology and oncology
- Clinical trials and results for drug development
- Digital and AI solutions in healthcare.
Investment Focus
Sanofi is primarily focused on several therapeutic areas, including immunology, neurology, oncology, rare diseases, rare blood disorders, cardiovascular diseases, and diabetes. These areas are part of their commitment to transforming scientific discoveries into healthcare solutions.
Other Considerations
Operates in over 100 countries; Engaged in numerous clinical trials globally; Committed to sustainability and equitable healthcare access.
Awards Recognition
- Sanofi iDEA-TECH Awards - Recognizes innovative research collaborations in North America.
- Sanofi iAwards - Acknowledges outstanding contributions in scientific research.
- Sanofi - Institut Pasteur Awards - Honors scientists for significant research in life sciences.
- Pharma Industry Awards - Sanofi won the National Biopharmaceutical Company of the Year award in Dublin.
- TORCH Awards - Acknowledges contributions of individuals affected by rare diseases.
Regulatory Approvals
- Sarclisa (isatuximab) - Approved by the FDA for use in combination with bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma.
- Dupixent (dupilumab) - Approved in over 60 countries for various indications, including as a treatment for chronic obstructive pulmonary disease (COPD) and atopic dermatitis.
- Enjaymo (sutimlimab) - Approved for the treatment of cold agglutinin disease (CAD).
- BEYFORTUS - Approved for use in the US and other countries to protect infants against respiratory syncytial virus (RSV).
- Tolebrutinib - A regulatory submission is under review in the EU and the FDA, with a target action date for the FDA decision set for September 28, 2025.
Partnerships
- Collaboration with Healx - Sanofi partnered with Healx, a UK-based biotech specializing in rare diseases, to utilize artificial intelligence for identifying novel rare disease indications (Genetic Engineering and Biotechnology News, 4 months ago).
- Partnership with Insilico Medicine - Sanofi collaborated with Insilico Medicine to achieve milestones in AI-facilitated drug discovery, leveraging Insilico's generative biology AI platform (EurekAlert!, 5 months ago).
- Agreement with Alloy Therapeutics - Sanofi entered a collaboration and license agreement with Alloy Therapeutics to use their AntiClastic™ Antisense Platform for developing treatments for central nervous system disorders (BioSpace, 2 months ago; Fierce Biotech, 2 months ago).
- Collaboration with OpenAI and Formation Bio - Sanofi is working with OpenAI and Formation Bio to develop AI-powered software aimed at accelerating drug development processes (Drug Discovery & Development, 10 months ago).
- Expansion with SK Bioscience - Sanofi expanded its collaboration with SK Bioscience on pneumococcal vaccines, committing significant financial resources to advance their joint projects (Fierce Biotech, 3 months ago).
Latest Funding Round
Sanofi's latest funding round was for Agomab Therapeutics, which secured $89 million in Series D funding announced on October 25, 2024. This funding is aimed at supporting clinical trials for fibrotic disease treatments. Additionally, Sanofi-backed Abcuro raised $200 million in Series C funding on February 12, 2025, to support its anti-KLRG1 antibody through a phase 2/3 muscle disease trial.
Key Innovations
- Dupixent (IL4xIL13 mAb) - A monoclonal antibody for multiple indications, including ulcerative colitis and chronic obstructive pulmonary disease.
- SAR444336 - A non-beta IL2 Synthorin™ targeting inflammatory conditions.
- Amlitelimab (OX40L mAb) - Investigated for inflammatory conditions like celiac disease and systemic sclerosis.
- Balinatunfib - An oral TNFR1 signaling inhibitor for Crohn’s disease and rheumatoid arthritis.
- Frexalimab (CD40L mAb) - Targeting type 1 diabetes and systemic lupus erythematosus.
Find more companies like Sanofi
Financial Overview
$133BTotal Raised
Sanofi's latest funding round was for Agomab Therapeutics, which secured $89 million in Series D funding announced on October 25, 2024. This funding is aimed at supporting clinical trials for fibrotic disease treatments. Additionally, Sanofi-backed Abcuro raised $200 million in Series C funding on February 12, 2025, to support its anti-KLRG1 antibody through a phase 2/3 muscle disease trial.
